AU2021240344A1 - 5-amino-8-(4-pyridyl)-(1,2,4)triazolo(4,3-c)pyrimidin-3-one compounds for use against cancer - Google Patents

5-amino-8-(4-pyridyl)-(1,2,4)triazolo(4,3-c)pyrimidin-3-one compounds for use against cancer Download PDF

Info

Publication number
AU2021240344A1
AU2021240344A1 AU2021240344A AU2021240344A AU2021240344A1 AU 2021240344 A1 AU2021240344 A1 AU 2021240344A1 AU 2021240344 A AU2021240344 A AU 2021240344A AU 2021240344 A AU2021240344 A AU 2021240344A AU 2021240344 A1 AU2021240344 A1 AU 2021240344A1
Authority
AU
Australia
Prior art keywords
methyl
amino
triazolo
pyrimidin
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021240344A
Other languages
English (en)
Inventor
Stephen Philippe Andrews
Giles Albert Brown
Miles Stuart Congreve
Jonathan Stephen Mason
Rebecca PAUL
Christine Mary Richardson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Nxera Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma UK Ltd filed Critical Nxera Pharma UK Ltd
Publication of AU2021240344A1 publication Critical patent/AU2021240344A1/en
Assigned to NXERA PHARMA UK LIMITED reassignment NXERA PHARMA UK LIMITED Amend patent request/document other than specification (104) Assignors: HEPTARES THERAPEUTICS LIMITED
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021240344A 2020-03-26 2021-03-25 5-amino-8-(4-pyridyl)-(1,2,4)triazolo(4,3-c)pyrimidin-3-one compounds for use against cancer Pending AU2021240344A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994908P 2020-03-26 2020-03-26
US62/994,908 2020-03-26
PCT/EP2021/057806 WO2021191378A1 (en) 2020-03-26 2021-03-25 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer

Publications (1)

Publication Number Publication Date
AU2021240344A1 true AU2021240344A1 (en) 2022-10-27

Family

ID=75339740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021240344A Pending AU2021240344A1 (en) 2020-03-26 2021-03-25 5-amino-8-(4-pyridyl)-(1,2,4)triazolo(4,3-c)pyrimidin-3-one compounds for use against cancer

Country Status (8)

Country Link
US (1) US20230271964A1 (enExample)
EP (1) EP4126872A1 (enExample)
JP (1) JP7675094B2 (enExample)
KR (1) KR20230049579A (enExample)
CN (1) CN115867282B (enExample)
AU (1) AU2021240344A1 (enExample)
CA (1) CA3176944A1 (enExample)
WO (1) WO2021191378A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20241731A1 (es) * 2022-02-01 2024-08-19 Lilly Co Eli Procesos para la preparacion de degradadores selectivos del receptor de estrogeno
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
EP2038285B1 (en) 2006-06-26 2010-02-17 Schering Corporation Adenosine a2a receptor antagonists
JP2011513417A (ja) * 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
CN103261202B (zh) 2010-09-24 2016-01-20 阿迪维纳斯疗法有限公司 作为腺苷受体拮抗剂的稠合三环化合物
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
KR20190129851A (ko) 2017-03-16 2019-11-20 지앙수 헨그루이 메디슨 컴퍼니 리미티드 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도

Also Published As

Publication number Publication date
JP7675094B2 (ja) 2025-05-12
EP4126872A1 (en) 2023-02-08
CA3176944A1 (en) 2021-09-30
CN115867282B (zh) 2025-05-27
CN115867282A (zh) 2023-03-28
KR20230049579A (ko) 2023-04-13
US20230271964A1 (en) 2023-08-31
JP2023519362A (ja) 2023-05-10
WO2021191378A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
CN112513029B (zh) 含氮芳基磷氧化物类衍生物、其制备方法和应用
JP7138724B2 (ja) 四環式ヘテロアリール化合物
AU2019287295B2 (en) Purinone compounds and their use in treating cancer
JP6159028B2 (ja) Ｓｙｋ阻害剤
KR101862493B1 (ko) Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체
WO2021191378A1 (en) 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer
AU2021281176B2 (en) Compounds useful for inhibiting CDK7
CN115867550B (zh) 三唑酮化合物
CN115867280B (zh) 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
HK40088927A (en) Triazolone compounds
HK40088927B (en) Triazolone compounds
CN119219637A (zh) 芳杂双环化合物及其抗病毒用途
EA045750B1 (ru) Ингибиторы g12d kras
TW202504586A (zh) 治療發炎性疾病之方法
CN117813309A (zh) 作为pd-l1相互作用的免疫调节剂的化合物